Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 25.3637 1.58% 0.39
SUPN closed down 3.92 percent on Tuesday, March 2, 2021, on 1.52 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical SUPN trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 1.72%
Below Lower BB Weakness 1.72%
Down 3 Days in a Row Weakness 1.72%
Down 4 Days in a Row Weakness 1.72%
Lower Bollinger Band Touch Weakness 1.72%
Oversold Stochastic Weakness 1.72%
MACD Bearish Centerline Cross Bearish -2.27%
Lower Bollinger Band Walk Weakness -2.27%
Stochastic Reached Oversold Weakness -2.27%
Below Lower BB Weakness -2.27%
Older End-of-Day Signals for SUPN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 2 hours ago
Up 2% about 2 hours ago
Down 1% about 6 hours ago
Rose Above Lower Bollinger Band about 6 hours ago
Up 1% about 6 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Supernus Pharmaceuticals, Inc. Description

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Research Clinical Trial Chloride Neurology Epilepsy Depression Attention Deficit Attention Deficit Hyperactivity Disorder Clinical Trial Product Hyperactivity Disorder Central Nervous System Disease Central Nervous System Diseases Treatment Of Central Nervous System Diseases Treatment Of Depression Investigational New Drug Treatment Of Epilepsy

Is SUPN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 31.97
52 Week Low 13.12
Average Volume 657,860
200-Day Moving Average 23.77
50-Day Moving Average 28.02
20-Day Moving Average 29.36
10-Day Moving Average 28.56
Average True Range 1.45
ADX 29.13
+DI 16.87
-DI 30.86
Chandelier Exit (Long, 3 ATRs ) 27.63
Chandelier Exit (Short, 3 ATRs ) 29.23
Upper Bollinger Band 32.61
Lower Bollinger Band 26.10
Percent B (%b) -0.17
BandWidth 22.19
MACD Line -0.39
MACD Signal Line 0.30
MACD Histogram -0.6903
Fundamentals Value
Market Cap 1.32 Billion
Num Shares 52.7 Million
EPS 2.41
Price-to-Earnings (P/E) Ratio 10.36
Price-to-Sales 2.45
Price-to-Book 1.62
PEG Ratio 1.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.33
Resistance 3 (R3) 27.56 27.01 26.93
Resistance 2 (R2) 27.01 26.41 26.89 26.80
Resistance 1 (R1) 25.99 26.04 25.72 25.76 26.67
Pivot Point 25.44 25.44 25.30 25.32 25.44
Support 1 (S1) 24.42 24.84 24.15 24.19 23.27
Support 2 (S2) 23.87 24.47 23.75 23.14
Support 3 (S3) 22.85 23.87 23.01
Support 4 (S4) 22.62